vs

Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and Paycom (PAYC). Click either name above to swap in a different company.

Amneal Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($722.5M vs $544.3M, roughly 1.3× Paycom). Paycom runs the higher net margin — 20.9% vs 10.8%, a 10.1% gap on every dollar of revenue. On growth, Paycom posted the faster year-over-year revenue change (10.2% vs 3.9%). Over the past eight quarters, Paycom's revenue compounded faster (4.3% CAGR vs 1.5%).

Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.

Paycom Software, Inc., known simply as Paycom, is an online payroll and human resource software provider based in Oklahoma City, Oklahoma with offices throughout the United States. It is attributed with being one of the first fully online payroll providers. Founded in 1998, it reported annual revenue of $2.052 billion for 2025, up from $1.883 billion for 2024.

AMRX vs PAYC — Head-to-Head

Bigger by revenue
AMRX
AMRX
1.3× larger
AMRX
$722.5M
$544.3M
PAYC
Growing faster (revenue YoY)
PAYC
PAYC
+6.3% gap
PAYC
10.2%
3.9%
AMRX
Higher net margin
PAYC
PAYC
10.1% more per $
PAYC
20.9%
10.8%
AMRX
Faster 2-yr revenue CAGR
PAYC
PAYC
Annualised
PAYC
4.3%
1.5%
AMRX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRX
AMRX
PAYC
PAYC
Revenue
$722.5M
$544.3M
Net Profit
$78.0M
$113.8M
Gross Margin
44.3%
83.9%
Operating Margin
19.6%
28.9%
Net Margin
10.8%
20.9%
Revenue YoY
3.9%
10.2%
Net Profit YoY
410.5%
0.2%
EPS (diluted)
$0.19
$2.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRX
AMRX
PAYC
PAYC
Q1 26
$722.5M
Q4 25
$814.3M
$544.3M
Q3 25
$784.5M
$493.3M
Q2 25
$724.5M
$483.6M
Q1 25
$695.4M
$530.5M
Q4 24
$730.5M
$493.9M
Q3 24
$702.5M
$451.9M
Q2 24
$701.8M
$437.5M
Net Profit
AMRX
AMRX
PAYC
PAYC
Q1 26
$78.0M
Q4 25
$35.1M
$113.8M
Q3 25
$2.4M
$110.7M
Q2 25
$22.4M
$89.5M
Q1 25
$12.2M
$139.4M
Q4 24
$-31.1M
$113.6M
Q3 24
$-156.0K
$73.3M
Q2 24
$6.0M
$68.0M
Gross Margin
AMRX
AMRX
PAYC
PAYC
Q1 26
44.3%
Q4 25
36.5%
83.9%
Q3 25
34.9%
82.7%
Q2 25
39.5%
81.9%
Q1 25
36.8%
84.1%
Q4 24
36.0%
83.1%
Q3 24
38.4%
80.5%
Q2 24
35.6%
80.8%
Operating Margin
AMRX
AMRX
PAYC
PAYC
Q1 26
19.6%
Q4 25
13.8%
28.9%
Q3 25
9.0%
22.8%
Q2 25
15.4%
23.2%
Q1 25
14.4%
34.9%
Q4 24
10.4%
30.1%
Q3 24
12.6%
23.2%
Q2 24
13.6%
21.7%
Net Margin
AMRX
AMRX
PAYC
PAYC
Q1 26
10.8%
Q4 25
4.3%
20.9%
Q3 25
0.3%
22.4%
Q2 25
3.1%
18.5%
Q1 25
1.8%
26.3%
Q4 24
-4.3%
23.0%
Q3 24
-0.0%
16.2%
Q2 24
0.9%
15.5%
EPS (diluted)
AMRX
AMRX
PAYC
PAYC
Q1 26
$0.19
Q4 25
$0.10
$2.06
Q3 25
$0.01
$1.96
Q2 25
$0.07
$1.58
Q1 25
$0.04
$2.48
Q4 24
$-0.10
$2.04
Q3 24
$0.00
$1.31
Q2 24
$0.02
$1.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRX
AMRX
PAYC
PAYC
Cash + ST InvestmentsLiquidity on hand
$197.7M
$370.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.7B
Total Assets
$3.5B
$7.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRX
AMRX
PAYC
PAYC
Q1 26
$197.7M
Q4 25
$282.0M
$370.0M
Q3 25
$201.2M
$375.0M
Q2 25
$71.5M
$532.2M
Q1 25
$59.2M
$520.8M
Q4 24
$110.6M
$402.0M
Q3 24
$74.0M
$325.8M
Q2 24
$43.8M
$346.5M
Total Debt
AMRX
AMRX
PAYC
PAYC
Q1 26
Q4 25
$2.6B
Q3 25
$2.6B
Q2 25
$2.2B
Q1 25
$2.2B
Q4 24
$2.4B
Q3 24
$2.4B
Q2 24
$2.4B
Stockholders' Equity
AMRX
AMRX
PAYC
PAYC
Q1 26
Q4 25
$-70.8M
$1.7B
Q3 25
$-109.5M
$1.7B
Q2 25
$-112.1M
$1.8B
Q1 25
$-131.7M
$1.7B
Q4 24
$-109.3M
$1.6B
Q3 24
$-93.4M
$1.5B
Q2 24
$-57.5M
$1.4B
Total Assets
AMRX
AMRX
PAYC
PAYC
Q1 26
$3.5B
Q4 25
$3.7B
$7.6B
Q3 25
$3.6B
$4.2B
Q2 25
$3.4B
$4.0B
Q1 25
$3.4B
$4.6B
Q4 24
$3.5B
$5.9B
Q3 24
$3.5B
$3.5B
Q2 24
$3.5B
$4.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRX
AMRX
PAYC
PAYC
Operating Cash FlowLast quarter
$196.1M
Free Cash FlowOCF − Capex
$122.6M
FCF MarginFCF / Revenue
22.5%
Capex IntensityCapex / Revenue
13.5%
Cash ConversionOCF / Net Profit
1.72×
TTM Free Cash FlowTrailing 4 quarters
$408.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRX
AMRX
PAYC
PAYC
Q1 26
Q4 25
$130.3M
$196.1M
Q3 25
$118.5M
$177.8M
Q2 25
$83.8M
$122.5M
Q1 25
$7.4M
$182.5M
Q4 24
$118.1M
$160.4M
Q3 24
$141.8M
$92.8M
Q2 24
$39.7M
$132.1M
Free Cash Flow
AMRX
AMRX
PAYC
PAYC
Q1 26
Q4 25
$108.5M
$122.6M
Q3 25
$106.2M
$79.8M
Q2 25
$61.0M
$60.8M
Q1 25
$-5.8M
$144.8M
Q4 24
$102.9M
$109.0M
Q3 24
$124.8M
$44.6M
Q2 24
$29.0M
$86.5M
FCF Margin
AMRX
AMRX
PAYC
PAYC
Q1 26
Q4 25
13.3%
22.5%
Q3 25
13.5%
16.2%
Q2 25
8.4%
12.6%
Q1 25
-0.8%
27.3%
Q4 24
14.1%
22.1%
Q3 24
17.8%
9.9%
Q2 24
4.1%
19.8%
Capex Intensity
AMRX
AMRX
PAYC
PAYC
Q1 26
Q4 25
2.7%
13.5%
Q3 25
1.6%
19.9%
Q2 25
3.2%
12.8%
Q1 25
1.9%
7.1%
Q4 24
2.1%
10.4%
Q3 24
2.4%
10.7%
Q2 24
1.5%
10.4%
Cash Conversion
AMRX
AMRX
PAYC
PAYC
Q1 26
Q4 25
3.72×
1.72×
Q3 25
50.00×
1.61×
Q2 25
3.74×
1.37×
Q1 25
0.61×
1.31×
Q4 24
1.41×
Q3 24
1.27×
Q2 24
6.62×
1.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRX
AMRX

Segment breakdown not available.

PAYC
PAYC

Recurring$510.3M94%
Interest On Funds Held For Clients$27.2M5%
Implementation And Other$6.8M1%

Related Comparisons